인공 장기 및 메디컬 바이오닉스 시장 보고서 : 제품 유형, 용도, 지역별(2025-2033년)

The global artificial vital organs and medical bionics market size reached USD 49.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 74.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.48% during 2025-2033. The rising prevalence of respiratory ailments, cirrhosis, and heart and liver failures, the increasing geriatric population that is highly prone to organ disorders, and various technological advancements represent some of the key factors driving the market.

Artificial vital organs, often referred to as artificial organs or bioartificial organs, are man-made devices designed to mimic the functions of natural organs within the human body. These devices are developed to serve as temporary or permanent replacements for malfunctioning or failed biological organs, helping patients maintain essential bodily functions and, in some cases, even enhancing them. On the other hand, medical bionics is a field of medical science and engineering that focuses on the development and integration of biological and artificial components to restore or enhance the functioning of the human body.

Currently, there is a notable surge in the prevalence of various medical conditions, including respiratory disorders, cirrhosis, as well as heart, kidney, and liver failures. This surge is closely tied to the expanding healthcare sector and serves as a significant catalyst for market growth. Furthermore, the increasing elderly population, which is particularly susceptible to organ-related ailments worldwide, is making a substantial contribution to the market's expansion. Moreover, the continuous development of innovative products, such as fully functional artificial hearts, livers, lungs, urethras, windpipes, and kidneys, is exerting a positive impact on market dynamics. Additionally, major market players are making substantial investments in research and development (R&D) endeavors, aimed at introducing cutting-edge methods of organ regeneration through engineered tissues. This ongoing innovation is fostering a promising outlook for the market. Besides this, there is a rising demand for artificial organs, driven by the emergence of bioartificial organs that offer improved survival rates and faster patient recovery. This growing demand is further propelled by the implementation of life-saving technologies like the bridge to transplant and the bridge to recovery in critical medical cases, further reinforcing market growth.

Artificial Vital Organs and Medical Bionics Market Trends/Drivers:

Rising prevalence of respiratory ailments, cirrhosis, and organ failures

There has been a notable increase in the prevalence of respiratory ailments such as chronic obstructive pulmonary disease (COPD) and lung infections. Patients with severe respiratory issues often require artificial lungs or other assistive devices to breathe adequately. Moreover, liver diseases, including cirrhosis, have seen a rise due to various factors like excessive alcohol consumption, viral hepatitis infections, and non-alcoholic fatty liver disease. In advanced stages, cirrhosis may necessitate liver transplantation, and artificial livers can serve as a bridge to transplantation or even a long-term solution. Besides, heart and liver failures are significant health concerns worldwide. Conditions like congestive heart failure and end-stage liver disease are on the rise due to factors such as an aging population, obesity, and lifestyle choices. Artificial hearts and liver support systems play a crucial role in providing life-saving solutions while patients await transplantation or as a permanent support option.

Increasing geriatric population across the globe

The global demographic landscape is shifting toward an aging population. Elderly individuals are more susceptible to organ disorders due to the natural aging process, making them a key demographic for artificial vital organ interventions. Besides, the elderly population is more prone to chronic medical conditions, including cardiovascular diseases, respiratory ailments, and kidney disorders. These conditions frequently require interventions such as artificial hearts, lungs, or kidneys to manage or improve the patient's quality of life. Medical bionics, such as pacemakers and cochlear implants, are also commonly used in elderly individuals to address age-related health issues. Artificial vital organs and medical bionics become crucial in extending and improving the lives of these elderly individuals, allowing them to enjoy a better quality of life in their later years.

Various technological advancements

Advancements in medical technology have significantly improved the design, functionality, and effectiveness of artificial vital organs and medical bionics. Moreover, full-functioning artificial organs, such as artificial hearts and lungs, have been developed with enhanced capabilities, allowing patients to lead more active lives. Besides, the integration of cutting-edge materials and bioengineering techniques has led to the creation of bioartificial organs that closely mimic natural organs, reducing the risk of rejection and improving overall patient outcomes. Additionally, leading players in the medical technology industry are investing heavily in research and development activities aimed at improving artificial vital organs and medical bionics. These investments result in the development of more sophisticated devices, enhanced materials, and improved surgical techniques, all of which contribute to better patient outcomes.

Key Market Segmentation:

Breakup by Product Type:

• Artificial Vital Organs
  • Artificial Liver
  • Artificial Heart
  • Artificial Pancreas
  • Artificial Kidney
  • Artificial Lungs
  • Oxygenators
• Medical Bionics
  • Bionic Limbs
  • Vision Bionics
  • Ear Bionics
  • Exoskeletons
  • Brain Bionics
  • Heart Valves
  • Cardiac Bionics

Artificial vital organs represent the most used product type

Artificial vital organs are designed to mimic the functions of natural vital organs such as the heart, lungs, kidneys, and liver. These devices are often used as a last resort when a patient's natural organs fail. They serve a life-saving function, providing crucial support to sustain a patient's life until a transplant becomes available or the natural organs recover. Moreover, there is a consistently high demand for artificial vital organs due of the prevalence of organ failure and the limited availability of organ donors. Individuals worldwide suffer from conditions that can lead to organ failure, and the demand for replacement organs far exceeds the supply. Artificial vital organs bridge this gap by offering a viable solution to patients in critical need.

Breakup by Application:

• Hospitals
• Clinics
• Others

Hospitals are a primary application for artificial vital organs and medical bionics. In these healthcare facilities, artificial vital organs such as artificial hearts, lungs, and kidneys are often used to support patients with organ failure while they await transplants. Additionally, medical bionics, including devices like cochlear implants and bionic limbs, may be provided to patients in hospital settings to improve their quality of life and functional capabilities.

Clinics, including specialized medical centers and outpatient facilities, play a crucial role in the application of artificial vital organs and medical bionics. These settings are where patients may receive diagnosis, consultation, and follow-up care related to these advanced medical technologies. Clinics often offer services related to the assessment, fitting, and maintenance of medical bionics, making them essential in the continuum of care.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America, particularly the United States and Canada, boasts a highly advanced healthcare infrastructure with state-of-the-art medical facilities and research institutions. This infrastructure fosters innovation and the development of cutting-edge medical technologies, including artificial vital organs and medical bionics. Besides, the region is a global hub for medical research and development. Leading universities, medical centers, and private companies collaborate to push the boundaries of medical science. This collaborative environment accelerates the creation and commercialization of medical bionics and artificial vital organs. Moreover, the region has well-established regulatory bodies, such as the Food and Drug Administration (FDA) in the United States and Health Canada, which ensure the safety and efficacy of medical devices. A robust regulatory framework provides confidence to investors, manufacturers, and healthcare providers, encouraging the development and adoption of medical bionics.

Competitive Landscape:

The competitive landscape of the market is characterized by the presence of multiple players that include established brands, emerging startups, and specialty manufacturers. Presently, leading companies are heavily investing in R&D to develop innovative and advanced artificial vital organs and medical bionics. They focus on improving the performance, durability, and safety of these devices, as well as reducing their size and enhancing compatibility with the human body. They are also expanding their product portfolios to cover a broader range of medical bionics and artificial organs. This diversification allows them to address a wider array of medical conditions and patient needs. Besides, companies are acquiring or merging with other companies in the industry to expand capabilities, gain access to new technologies, and increase market share.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abiomed
• BiVACOR Inc
• CARMAT
• Cirtec Medical
• Edwards Lifesciences
• Ekso Bionics Holdings Inc.
• Nikkiso Co. Ltd.
• Second Sight Medical Products Inc
• SynCardia Systems LLC (Picard Medical Inc.)

Key Questions Answered in This Report

• 1.How big is the artificial vital organs and medical bionics market?
• 2.What is the expected growth rate of the global artificial vital organs and medical bionics market during 2025-2033?
• 3.What are the key factors driving the global artificial vital organs and medical bionics market?
• 4.What has been the impact of COVID-19 on the global artificial vital organs and medical bionics market?
• 5.What is the breakup of the global artificial vital organs and medical bionics market based on the product type?
• 6.What are the key regions in the global artificial vital organs and medical bionics market?
• 7.Who are the key players/companies in the global artificial vital organs and medical bionics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Artificial Vital Organs and Medical Bionics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Artificial Vital Organs
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Artificial Liver
    • 6.1.2.2 Artificial Heart
    • 6.1.2.3 Artificial Pancreas
    • 6.1.2.4 Artificial Kidney
    • 6.1.2.5 Artificial Lungs
    • 6.1.2.6 Oxygenators
  • 6.1.3 Market Forecast
• 6.2 Medical Bionics
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Bionic Limbs
    • 6.2.2.2 Vision Bionics
    • 6.2.2.3 Ear Bionics
    • 6.2.2.4 Exoskeletons
    • 6.2.2.5 Brain Bionics
    • 6.2.2.6 Heart Valves
    • 6.2.2.7 Cardiac Bionics
  • 6.2.3 Market Forecast

7 Market Breakup by Application

• 7.1 Hospitals
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Clinics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abiomed
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 BiVACOR Inc
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 CARMAT
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
  • 13.3.4 Cirtec Medical
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
  • 13.3.5 Edwards Lifesciences
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 Ekso Bionics Holdings Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Nikkiso Co. Ltd.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Second Sight Medical Products Inc
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
  • 13.3.9 SynCardia Systems LLC (Picard Medical Inc.)
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 SWOT Analysis